26
|
Grosso F, Ceresoli G, Roveta A, Bearz A, Valentino F, Novello S, Santoro A, Cognetti F, Amadori D, Dall'olio F, Zucchi L, Pastorino U, Rea F, Boni C, Maggioni P, Gallizzi G, Maconi A, Scagliotti G, Magnani C. Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Novello S, Nowak A, Grosso F, Steele N, Popat S, Greillier L, John T, Leighl N, Reck M, Pavlakis N, Sorensen J, Planchard D, Ceresoli G, Hughes B, Mazieres J, Socinski M, von Wangenheim U, Barrueco J, Morsli N, Scagliotti G. Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx389.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Grosso F, Croce A, Trincheri NF, Mariani N, Libener R, Degiovanni D, Rinaudo C. Asbestos fibres detected by scanning electron microscopy in the gallbladder of patients with malignant pleural mesothelioma (MPM). J Microsc 2017; 266:48-54. [PMID: 28066892 DOI: 10.1111/jmi.12517] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 10/14/2016] [Accepted: 11/30/2016] [Indexed: 12/01/2022]
Abstract
Gallbladders from patients affected by both malignant pleural mesothelioma (MPM) and important gallbladder disorders were analyzed to verify the presence of asbestos fibres. Histological thin sections were analyzed by optical microscope and variable pressure scanning electron microscopy coupled with energy dispersive spectroscopy, allowing morphological and chemical characterization of each inorganic phase observed. Fibres of chrysotile and crocidolite, minerals regulated as asbestos, were identified. By immunohistochemical analysis, connective tissue was recognized as the incorporation site. These findings confirm that asbestos fibres can reach the gallbladders of patients with MPM, for whom the development of respiratory diseases confirms asbestos exposure.
Collapse
|
29
|
Grosso F, Roveta A, Gallizzi G, Muzio A, Zai S, Ugo F, Aurelio A, Libener R, Mancuso M, Ferretti G, Franzone P, Pastormerlo M, Piccolini E, Degiovanni D, Numico G. Frequency, patterns and prognostic impact of distant metastases in a large mono-institutional series of malignant pleural mesothelioma (MPM): Not necessarily bad news. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw391.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Gallizzi G, Grosso F, Kasa A, Oneglia B, Ballarino P, Roveta A, Giaretto L, Muzio A, Numico G, Degiovanni D. Frequency and intensity of symptoms and disease awareness in a large mono-institutional series of Malignant Pleural Mesothelioma (MPM) patients followed within a simultaneous care program. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw336.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Ippoliti R, Randi L, Grosso F, Numico G. Economic burden of patients with Malignant Pleural Mesothelioma in a high prevalence center. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Grosso F, Mądrzak J, Crinò L, Chella A, Weinberg U, Ceresoli G. 215TiP: STELLAR – A phase II trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30322-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
33
|
Ceresoli G, Zucali P, Grosso F, Mencoboni M, Sauta M, Soto Parra H, Pasello G, Cortinovis D, Perrino M, Muzio A, Bruzzone A, De Vincenzo F, Degiovanni D, Bonomi M, Simonelli M, Beretta G, Giordano L, Santoro A. Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
34
|
Cortinovis D, Hollander L, Floriani I, Grosso F, Marinello A, Ceresoli G, Pacchetti I, Zucali P, Tiseo M, D'Incalci M, Canova S, Ugo F, Vukcaj S, Abbate M, Zai S, Bidoli P. Activity and Safety of Trabectedin in patients with Sarcomatoid / Biphasic Malignant Pleural Mesothelioma (MPM). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Hollander L, Cortinovis D, Floriani I, Grosso F, Ceresoli G, Zucali P, D'Incalci M, Tiseo M, Abbate M, Canova S, Ugo F, Marchini S, Allavena P, Bianchi M, Corli O, Vukcaj S, Zai S, Bidoli P. ATREUS Trial: A Phase II Study On The Activity Of Trabectedin In Pretreated Epithelioid Or Biphasic/Sarcomatoid Malignant Pleural Mesothelioma (MPM). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.43] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Ceresoli GL, Grosso F, Zucali PA, Mencoboni M, Pasello G, Ripa C, Degiovanni D, Simonelli M, Bruzzone A, Dipietrantonj C, Piccolini E, Beretta GD, Favaretto AG, Giordano L, Santoro A, Botta M. Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. Br J Cancer 2014; 111:220-6. [PMID: 24918816 PMCID: PMC4102949 DOI: 10.1038/bjc.2014.312] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2014] [Revised: 04/29/2014] [Accepted: 05/12/2014] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. There are no specific guidelines for their management. METHODS The clinical records of elderly patients (⩾70 years old) with MPM referred from January 2005 to November 2011 to six Italian Centres were reviewed. Age, gender, histology, International Mesothelioma Interest Group (IMIG) stage, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), Charlson Comorbidity Index (CCI) and treatment modalities were analysed and correlated to overall survival (OS). RESULTS In total, 241 patients were identified. Charlson Comorbidity Index was ⩾1 in 92 patients (38%). Treatment was multimodality therapy including surgery in 18, chemotherapy alone in 180 (75%) and best supportive care in 43 cases (18%). Chemotherapy was mainly pemetrexed based. Median OS was 11.4 months. Non-epithelioid histology (HR 2.32; 95% CI 1.66-3.23, P<0.001), age ⩾75 years (HR 1.44; 95% CI 1.08-1.93, P=0.014), advanced (III-IV) stage (HR 1.47; 95% CI 1.09-1.98, P=0.011) and CCI⩾1 (HR 1.38; 95% CI 1.02-1.85, P=0.034) were associated to a shorter OS. Treatment with pemetrexed was associated with improved OS (HR 0.40; 95% CI 0.28-0.56, P<0.001). CONCLUSIONS Non-epithelioid histology, age ⩾75 years, advanced IMIG stage and presence of comorbidities according to CCI were significant prognostic factors in elderly patients with MPM. Treatment with pemetrexed-based chemotherapy was feasible in this setting. Prospective dedicated trials in MPM elderly patients selected according to prognostic factors including comorbidity scales are warranted.
Collapse
|
37
|
Casali PG, Bertulli R, Fumagalli E, Coco P, Grosso F, Stacchiotti S. Some Lessons Learned from Imatinib Mesylate Clinical Development in Gastrointestinal Stromal Tumors. J Chemother 2013; 16 Suppl 4:55-8. [PMID: 15688611 DOI: 10.1179/joc.2004.16.supplement-1.55] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Imatinib mesylate is a molecular-targeted agent, shown to be effective in chronic myeloid leukemia and gastrointestinal stromal tumors (GIST). The latter may currently serve as a model on which speculating how the future of molecular-targeted therapy in solid tumors will be. So far, some lessons have been learnt. 1) Molecular-targeted therapy can be effective in the advanced disease setting, resulting in major tumor responses. 2) Patterns of tumor responses may be peculiar, radiologically and pathologically. 3) Anti-tumor activity may be highly predictable by assessing tumor molecular biology. 4) The methodology of clinical development of molecular-targeted agents may differ from standard chemotherapy in some respects, because, say, the preclinical rationale may be stronger, thus increasing the Bayesian prior probability of efficacy, or the optimal dose cannot be determined separately from the assessment of activity and efficacy. 5) Molecular-targeted agents will hardly remain "orphan drugs", if effective. 6) While an obvious impact on survival in the advanced disease setting has been clearly demonstrated, the biologic and clinical impact of molecular-targeted therapy still needs to be elucidated. Its eradicating capabilities, as well as the implications of secondary resistance, are to be understood. 7) Integrated, multimodality approaches, including surgery, may still be of value in the molecular-targeted therapy era.
Collapse
|
38
|
Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, Gronchi A, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JMF, D'Incalci M. Mode of action of trabectedin in myxoid liposarcomas. Oncogene 2013; 33:5201-10. [PMID: 24213580 DOI: 10.1038/onc.2013.462] [Citation(s) in RCA: 95] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2013] [Revised: 09/04/2013] [Accepted: 09/05/2013] [Indexed: 12/11/2022]
Abstract
To elucidate the mechanisms behind the high sensitivity of myxoid/round cell liposarcoma (MRCL) to trabectedin and the suggested selectivity for specific subtypes, we have developed and characterized three MRCL xenografts, namely ML017, ML015 and ML004 differing for the break point of the fusion gene FUS-CHOP, respectively of type I, II and III. FUS-CHOP binding to the promoters of some target genes such as Pentraxin 3 or Fibronectin 1, assessed by chromatin immunoprecipitation, was strongly reduced in the tumor 24 h after the first or the third weekly dose of trabectedin, indicating that the drug at therapeutic doses causes a detachment of the FUS-CHOP chimera from its target promoters as previously shown in vitro. Moreover, the higher sensitivity of MRCL types I and II appears to be related to a more prolonged block of the transactivating activity of the fusion protein. Doxorubicin did not affect the binding of FUS-CHOP to target promoters. Histologically, the response to trabectedin in ML017 and ML015 was associated with a marked depletion of non-lipogenic tumoral cells and vascular component, as well as lipidic maturation as confirmed by PPARγ2 expression in western Blot. By contrast, in ML004 no major changes either in the cellularity or in the amount of mature were found, and consistently PPARγ2 was null. In conclusion, the data support the view that the selective mechanism of action of trabectedin in MRCL is specific and related to its ability to cause a functional inactivation of the oncogenic chimera with consequent derepression of the adypocytic differentiation.
Collapse
|
39
|
Grosso F, Degiovanni D, Roveta A, Barbero S, Libener R, Musante F, Testori O, Mirabelli D, Betta P, Botta M. Prevalence, Clinical Features and Prognosis of Diffuse Malignant Peritoneal Mesothelioma (DMPM): Do Patients in Clinical Trials Reflect the real World? Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33329-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
40
|
Colucci A, Bianco A, Pomara F, Petrucci M, Grosso F, De Vita A, Adamo V, Palma A. Disease management of type 2 diabetes: a follow-up analysis in a sanitary district of Sicily. MINERVA GASTROENTERO 2011; 57:241-246. [PMID: 21769074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
AIM The aim of this paper was to analyze the Disease management of type 2 diabetes in a sanitary district of the Sicily Region (Italy). METHODS In a population of 9 698 subjects, we selected patients with known type 2 diabetes: a cohort of 385 subjects, (206 women and 179 men) following up for one year. Prevalence of type 2 diabetes in the analyzed population was 3.97%. A great lot of cohort was on a diet. RESULTS After one year, a per cent reduction of obese and overweight subjects was observed. No differences were observed for Body Mass Index (BMI) at the beginning and at the end of the study. After one year, through educational meetings with the doctor, a significant increase of knowledge on the patient's conditions and on the diabetes complications was verified, but our data showed persistent poor attention by doctors. The poor knowledge of patients led to a difficult disease management. After one year, a great lot of cohort used antistroke and cardiovascular disease therapy, reducing significantly the cardiovascular disease risk. However, our study also highlights a gap between the therapeutic guidelines and the actual treatment, with wide variability in the delivery of secondary prevention. CONCLUSION. Our study showed that a persevering warning and a constant adjournment of doctors improves the disease management, reducing complications risk in type 2 diabetes patients.
Collapse
|
41
|
Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, Damia G, Ganzinelli M, Marangon E, Sala F, Clivio L, Chiorino G, Di Giandomenico S, Rocchi M, Capozzi O, Margison GP, Watson AJ, Caccuri AM, Pastore A, Fossati A, Mantovani R, Grosso F, Tercero JC, Erba E, D'Incalci M. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. Int J Cancer 2011; 131:59-69. [PMID: 21805478 DOI: 10.1002/ijc.26340] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2011] [Accepted: 07/21/2011] [Indexed: 02/05/2023]
Abstract
Myxoid Liposarcomas (MLS), characterized by the expression of FUS-CHOP fusion gene are clinically very sensitive to the DNA binding antitumor agent, trabectedin. However, resistance eventually occurs, preventing disease eradication. To investigate the mechanisms of resistance, a trabectedin resistant cell line, 402-91/ET, was developed. The resistance to trabectedin was not related to the expression of MDR related proteins, uptake/efflux of trabectedin or GSH levels that were similar in parental and resistant cells. The 402-91/ET cells were hypersensitive to UV light because of a nucleotide excision repair defect: XPG complementation decreased sensitivity to UV rays, but only partially to trabectedin. 402-91/ET cells showed collateral sensitivity to temozolomide due to the lack of O(6) -methylguanine-DNA-methyltransferase (MGMT) activity, related to the hypermethylation of MGMT promoter. In 402-91 cells chromatin immunoprecipitation (ChIP) assays showed that FUS-CHOP was bound to the PTX3 and FN1 gene promoters, as previously described, and trabectedin caused FUS-CHOP detachment from DNA. Here we report that, in contrast, in 402-91/ET cells, FUS-CHOP was not bound to these promoters. Differences in the modulation of transcription of genes involved in different pathways including signal transduction, apoptosis and stress response between the two cell lines were found. Trabectedin activates the transcription of genes involved in the adipogenic-program such as c/EBPα and β, in 402-91 but not in 402-91/ET cell lines. The collateral sensitivity of 402-91/ET to temozolomide provides the rationale to investigate the potential use of methylating agents in MLS patients resistant to trabectedin.
Collapse
|
42
|
Covaciu C, Grosso F, Pisaneschi E, Zambruno G, Gregersen P, Sommerlund M, Hertz J, Castiglia D. A founder synonymous COL7A1 mutation in three Danish families with dominant dystrophic epidermolysis bullosa pruriginosa identifies exonic regulatory sequences required for exon 87 splicing. Br J Dermatol 2011; 165:678-82. [DOI: 10.1111/j.1365-2133.2011.10414.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
43
|
Betta PG, Olivieri F, Lazzarini R, Ceka A, Graciotti L, Babini L, Rippo MR, Procopio A, Grosso F, Libener R. miRNAs signature in microdissected tissues and primary cultured cells of malignant mesotelioma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Grosso F, Roveta A, Bensi T, Trincheri NF, Libener R, Pavesi M, Giaretto L, Piccolini E, Botta M, Bottero G, Mirabelli D, Betta PG. Long-term survivors (LS) of malignant pleural mesothelioma (MPM): An effort to gain knowledge of this uncommon biology. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali P, Cesne AL, Jones R, Blay JY, Poveda A, Maki R, Nieto A, Tercero J, Rosell R. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. Eur J Cancer 2011; 47:1006-12. [DOI: 10.1016/j.ejca.2011.01.016] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2010] [Revised: 01/06/2011] [Accepted: 01/20/2011] [Indexed: 10/18/2022]
|
46
|
Grosso F, Quinteira S, Peixe L. Understanding the dynamics of imipenem-resistant Acinetobacter baumannii lineages within Portugal. Clin Microbiol Infect 2011; 17:1275-9. [PMID: 21375660 DOI: 10.1111/j.1469-0691.2011.03469.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A recent collection of 213 imipenem-resistant Acinetobacter baumannii (IRAB) clinical isolates was characterized for the presence of acquired carbapenem-hydrolysing class D β-lactamases (CHDLs) and clonality. A population structure analysis of IRAB was also conducted, with five molecular typing methods. Three main clusters, each one associated with a specific CHDL, were observed with multilocus sequence typing. Overall, our results suggest a switch in the dominant clone, with sequence type (ST) 92, carrying bla(OXA-23) (63.4%), replacing the closely related ST98, carrying bla(OXA-24/40) (22%). In addition, ST103, an independent lineage, was associated with bla(OXA-58) -carrying isolates (14.6%).
Collapse
|
47
|
Marchini S, Frapolli R, Nerini I, Pilotti S, Casali P, Grosso F, Sanfilippo R, Gronchi A, Tercero J, D'incalci M. 278 Myxoid liposarcoma tumors with different chimera subtypes xenografted in nude mice are characterized by different response to trabectedin and gene expression profile. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71985-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
48
|
Pomara F, Grosso F, Basile D, Polizzi V, Marcianò C, Adamo V, De Vita A, Petrucci M. [A pilot study on adolescents of both sexes. Correlation between phenotype, athletic performances and family history to type 2 diabetes]. Minerva Pediatr 2010; 62:425-430. [PMID: 20940677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The authors have studied the influence of family history of type 2 diabetes on the physical phenotype of 47 health adolescents. In both sexes groups with positive family history (FH+) had the highest values of stature and body weight (P<0.05 for males, not significant for females), waist circumference (P<0.05 for males, not significant for females), and wrist circumference (P=0.05 for males, not significant for females). Considering athletic performance, FH+ males showed a significant higher performance in power exercises than FH- males; no significant differences were found between FH+ and FH- female groups. The study confirms that family history of type 2 diabetes can induce in both sexes precocious phenotype and athletic performances linked-related variations; larger studies are necessary to confirm these data and to verify preventive interventions promoting significant life-style changes.
Collapse
|
49
|
Sanfilippo R, Grosso F, D'Incalci M, Dileo P, Pilotti S, Morosi C, Fiore M, Tercero JC, Gronchi A, Casali PG. Surgery of residual disease of myxoid liposarcoma (MLS) patients responding to trabectedin. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Betta P, Bensi T, Trincheri NF, Arnolfo E, Libener R, Botta M, Piccolini E, Bottero G, Grosso F, Orecchia S. Aurora B kinase and malignant mesothelioma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e21021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|